Goldman Capital Management Reduces Stake in Bacterin International Holdings Inc (BONE)
Goldman Capital Management Inc has reduced its exposure to Bacterin International Holdings Inc (NYSEMKT:BONE). In a recent filing with the Securities and Exchange Commission, the fund has revealed the reduction of its stake from 2.5 million shares reported in their latest 13F report to 1.5 million shares. Goldman Capital's current position accounts for 2.9% of the company's common stock.
Only 3 of the hedge funds we track are also invested in Bacterin International Holdings Inc (NYSEMKT:BONE). Samuel Isaly and his fund, Orbimed Advisors, have reported in their latest 13F filing the ownership of 1.75 million shares valued at $1.17 million. During the third quarter of 2013, James E. Flynn has decreased his fund's stake by 60%. Deerfield Management now holds 771,775 shares valued at a little over $0.5 million. Ending the list is Jim Simons. His fund, Renaissance Technologies, has initiated a position during Q3 and now owns 15,300 shares reportedly worth approximately $10,000.
Bacterin International Holdings Inc (NYSEMKT:BONE) engages in the production and sale of biologic products and has a worldwide market presence. So far this year the stock has fallen 70% to an all-time low of $0.38 per share. The company has a market cap of $20.7 million and a beta of 2.76, which makes it a very volatile stock. Bacterin International Holdings does not pay a dividend. For the three months ended September 30, 2013, the company posted revenues of $7.9 million, a 10% year-over-year decrease, and a loss of $0.08 per share. Analysts are more optimistic about the company's financial performance during the current quarter and expect revenues of $9.27 million and a loss per share of $0.06.